Држава: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
LETROZOLE
Caduceus Pharma Ltd
2.5 Milligram
Film Coated Tablet
2009-09-11
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Letrozole 2.5 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 2.5 mg letrozole. Excipient: Each tablet contains 58.4 mg lactose as lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Letrozole 2.5 mg film-coated tablets are yellow, round, lenticular, film-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. - Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years. - First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. - Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-oestrogens. Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ADULTS AND ELDERLY PATIENTS_ The recommended dose of letrozole is 2.5 mg once daily. No dose adjustment is required for elderly patients. In the adjuvant setting, it is recommended to treat for 5 years or until tumour relapse occurs. In the adjuvant setting, clinical experience is available for 2 years (median duration of treatment was 25 months). In the extended adjuvant setting, clinical experience is available for 4 years (median duration of treatment). In patients with advanced or metastatic disease, treatment with letrozole should continue until tumour progression if evident. _CHILDREN_ Not applicable. _PATIENTS WITH HEPATIC AND/OR RE Прочитајте комплетан документ